Related Experiment Video
Updated: Mar 10, 2026
In Vitro Tumor Cell Rechallenge For Predictive Evaluation of Chimeric Antigen Receptor T Cell Antitumor Function
Published on: February 27, 2019
Immunotherapy rechallenge after progression in non-small cell lung cancer: A systematic review and network
Ying Li1, Junfeng Zhao2, Jiaxuan Chen3
1Department of Respiratory Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250000, China.
Abstract:
To determine whether immunotherapy can be continued in patients with advanced non-small cell lung cancer (NSCLC) after initial immunotherapy. This study aimed to explore whether patients could benefit from immunotherapy after progression and identify the optimal treatment regimen. The included studies were classified into two groups based on whether patients continued immunotherapy rechallenge after disease progression: the immunotherapy rechallenge group and the non-immunotherapy group. The progression-free survival (PFS) and overall survival (OS) of patients in both groups were analyzed. Patients in the immunotherapy rechallenge group showed a significant advantage in PFS (HR: 0.65, p = 0.004) and OS (HR: 0.69, p = 0.013). In the analysis of different treatment regimens in the immunotherapy rechallenge group, immune checkpoint inhibitors (ICIs) + antiangiogenic therapy achieved the best PFS. These findings elucidate the role of ICI-based treatment strategies in patients with advanced NSCLC and are expected to supplement lung cancer immunotherapy guidelines.
More Related Videos
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
